



uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City

September 26, 2016

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Sept. 26, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that Matt Kapusta, interim chief executive officer, will present an overview of the company's programs and progress at the Jefferies Gene Editing/Gene Therapy Summit on Tuesday October 11th at the Jefferies Conference Center in New York City:

- **Jefferies Gene Editing/ Gene Therapy Summit Venue:**Jefferies Conference Center, New York City **Presenter:**Matt Kapusta, Interim Chief Executive Officer **Date and Time:**Tuesday, October 11th, 2:00 p.m. EDT

In addition, the company will be available for one-on-one meetings at the conference. The presentation will be available at the "Investors" section of the uniQure website and can be accessed one hour after the conclusion of the live event through: <http://www.uniqure.com/investors/shareholder-information/>.

About uniQure uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniqure.com

uniQure Forward-Looking Statement This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2016. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 m.cantor@uniQure.com

Eva Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 e.mulder@uniQure.com

PDF Version of Release <http://hugin.info/157414/R/2044359/763411.pdf>